589 related articles for article (PubMed ID: 27334498)
1. Efficacy and safety profile of linezolid in the treatment of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis: a systematic review and meta-analysis.
Agyeman AA; Ofori-Asenso R
Ann Clin Microbiol Antimicrob; 2016 Jun; 15(1):41. PubMed ID: 27334498
[TBL] [Abstract][Full Text] [Related]
2. Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial.
Lee M; Mok J; Kim DK; Shim TS; Koh WJ; Jeon D; Lee T; Lee SH; Kim JS; Park JS; Lee JY; Kim SY; Lee JH; Jo KW; Jhun BW; Kang YA; Ahn JH; Kim CK; Shin S; Song T; Shin SJ; Kim YR; Ahn H; Hahn S; Won HJ; Jang JY; Cho SN; Yim JJ
Trials; 2019 Jan; 20(1):57. PubMed ID: 30651149
[TBL] [Abstract][Full Text] [Related]
3. Linezolid for drug-resistant pulmonary tuberculosis.
Singh B; Cocker D; Ryan H; Sloan DJ
Cochrane Database Syst Rev; 2019 Mar; 3(3):CD012836. PubMed ID: 30893466
[TBL] [Abstract][Full Text] [Related]
4. Linezolid for the treatment of extensively drug-resistant tuberculosis: a systematic review and meta-analysis.
Lifan Z; Sainan B; Feng S; Siyan Z; Xiaoqing L
Int J Tuberc Lung Dis; 2019 Dec; 23(12):1293-1307. PubMed ID: 31931914
[No Abstract] [Full Text] [Related]
5. Linezolid for the treatment of complicated drug-resistant tuberculosis: a systematic review and meta-analysis.
Cox H; Ford N
Int J Tuberc Lung Dis; 2012 Apr; 16(4):447-54. PubMed ID: 22325685
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and tolerability of daily-half dose linezolid in patients with intractable multidrug-resistant tuberculosis.
Park IN; Hong SB; Oh YM; Kim MN; Lim CM; Lee SD; Koh Y; Kim WS; Kim DS; Kim WD; Shim TS
J Antimicrob Chemother; 2006 Sep; 58(3):701-4. PubMed ID: 16857689
[TBL] [Abstract][Full Text] [Related]
7. Systematic review and meta-analysis of the efficacy and safety of therapy with linezolid containing regimens in the treatment of multidrug-resistant and extensively drug-resistant tuberculosis.
Zhang X; Falagas ME; Vardakas KZ; Wang R; Qin R; Wang J; Liu Y
J Thorac Dis; 2015 Apr; 7(4):603-15. PubMed ID: 25973226
[TBL] [Abstract][Full Text] [Related]
8. Daily 300 mg dose of linezolid for multidrug-resistant and extensively drug-resistant tuberculosis: updated analysis of 51 patients.
Koh WJ; Kang YR; Jeon K; Kwon OJ; Lyu J; Kim WS; Shim TS
J Antimicrob Chemother; 2012 Jun; 67(6):1503-7. PubMed ID: 22403262
[TBL] [Abstract][Full Text] [Related]
9. Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis.
Sotgiu G; Centis R; D'Ambrosio L; Alffenaar JW; Anger HA; Caminero JA; Castiglia P; De Lorenzo S; Ferrara G; Koh WJ; Schecter GF; Shim TS; Singla R; Skrahina A; Spanevello A; Udwadia ZF; Villar M; Zampogna E; Zellweger JP; Zumla A; Migliori GB
Eur Respir J; 2012 Dec; 40(6):1430-42. PubMed ID: 22496332
[TBL] [Abstract][Full Text] [Related]
10. Treatment of Highly Drug-Resistant Pulmonary Tuberculosis.
Conradie F; Diacon AH; Ngubane N; Howell P; Everitt D; Crook AM; Mendel CM; Egizi E; Moreira J; Timm J; McHugh TD; Wills GH; Bateson A; Hunt R; Van Niekerk C; Li M; Olugbosi M; Spigelman M;
N Engl J Med; 2020 Mar; 382(10):893-902. PubMed ID: 32130813
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness and safety of imipenem/clavulanate and linezolid to treat multidrug and extensively drug-resistant tuberculosis at a referral hospital in Brazil.
Arbex MA; Bonini EH; Kawakame Pirolla G; D'Ambrosio L; Centis R; Migliori GB
Rev Port Pneumol (2006); 2016; 22(6):337-341. PubMed ID: 27481315
[TBL] [Abstract][Full Text] [Related]
12. Increasing pathomorphism of pulmonary tuberculosis: an observational study of slow clinical, microbiological and imaging response of lung tuberculosis to specific treatment. Which role for linezolid?
Manfredi R; Nanetti A; Dal Monte P; Calza L
Braz J Infect Dis; 2009 Aug; 13(4):297-303. PubMed ID: 20231995
[TBL] [Abstract][Full Text] [Related]
13. Bedaquiline and Linezolid for Extensively Drug-Resistant Tuberculosis in Pregnant Woman.
Jaspard M; Elefant-Amoura E; Melonio I; De Montgolfier I; Veziris N; Caumes E
Emerg Infect Dis; 2017 Oct; 23(10):1731-2. PubMed ID: 28792382
[TBL] [Abstract][Full Text] [Related]
14. Linezolid for patients with multidrug-resistant tuberculosis/extensively drug-resistant tuberculosis in China.
Zhang P; Tan J; Lin Y; Zhang H; Deng G; Chen X
Drug Discov Ther; 2022 May; 16(2):96-98. PubMed ID: 35444071
[TBL] [Abstract][Full Text] [Related]
15. Linezolid for the treatment of drug-resistant tuberculosis in children: a review and recommendations.
Garcia-Prats AJ; Rose PC; Hesseling AC; Schaaf HS
Tuberculosis (Edinb); 2014 Mar; 94(2):93-104. PubMed ID: 24388605
[TBL] [Abstract][Full Text] [Related]
16. Delamanid: From discovery to its use for pulmonary multidrug-resistant tuberculosis (MDR-TB).
Liu Y; Matsumoto M; Ishida H; Ohguro K; Yoshitake M; Gupta R; Geiter L; Hafkin J
Tuberculosis (Edinb); 2018 Jul; 111():20-30. PubMed ID: 30029909
[TBL] [Abstract][Full Text] [Related]
17. Treatment efficacy of drug-resistant tuberculosis in Bashkortostan, Russia: A retrospective cohort study.
Yunusbaeva M; Borodina L; Alekseev P; Davydov R; Yunusbaev U; Sharipov R; Bilalov F; Yunusbayev B
Int J Infect Dis; 2019 Apr; 81():203-209. PubMed ID: 30794942
[TBL] [Abstract][Full Text] [Related]
18. Substitution of ethambutol with linezolid during the intensive phase of treatment of pulmonary tuberculosis: study protocol for a prospective, multicenter, randomized, open-label, phase II trial.
Lee JY; Kim DK; Lee JK; Yoon HI; Jeong I; Heo E; Park YS; Lee JH; Park SS; Lee SM; Lee CH; Lee J; Choi SM; Park JS; Joh JS; Cho YJ; Lee YJ; Kim SJ; Hwang YR; Kim H; Ki J; Choi H; Han J; Ahn H; Hahn S; Yim JJ
Trials; 2017 Feb; 18(1):68. PubMed ID: 28193240
[TBL] [Abstract][Full Text] [Related]
19. Prevalence and treatment outcome of extensively drug-resistant tuberculosis plus additional drug resistance from the National Clinical Center for Tuberculosis in China: A five-year review.
Pang Y; Lu J; Huo F; Ma Y; Zhao L; Li Y; Liang Q; Chu N; Gao M; Huang H
J Infect; 2017 Nov; 75(5):433-440. PubMed ID: 28804028
[TBL] [Abstract][Full Text] [Related]
20. Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis.
Koh WJ; Kwon OJ; Gwak H; Chung JW; Cho SN; Kim WS; Shim TS
J Antimicrob Chemother; 2009 Aug; 64(2):388-91. PubMed ID: 19468028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
